- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06537609
En plattformforsøk for gramnegative blodstrømsinfeksjoner (BALANCE+)
BALANCE+: En plattformforsøk for gramnegative blodstrømsinfeksjoner
BALANCE+ is a perpetual multiple domain randomized controlled platform trial to evaluate various treatment strategies for Gram-negative bloodstream infections (GN BSIs). Each domain addresses critical questions in the management of GN BSIs, aiming to refine treatment strategies, enhance patient outcomes, and reduce antimicrobial resistance.
The initial vanguard pilot RCT (NCT05893147) started on 29 August 2023 and has successfully completed the pilot phase on 24-Apr-2024. All patients enrolled in the vanguard phase are part of the main platform trial.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
- Annen: De-escalation VS No De-escalation
- Annen: Oral beta-lactams VS non beta-lactams
- Annen: Central vascular catheter retention VS Central vascular catheter replacement
- Annen: Cephalosporin VS Carbapenem for low risk AmpC organisms
- Annen: Routine follow-up blood culture VS No routine follow-up blood culture
- Annen: 4-day versus 7- day antibiotic duration
Detaljert beskrivelse
BALANCE+ is an adaptive platform trial evaluating multiple treatment options in patients admitted to the hospital due to Gram negative bloodstream infections (BSIs). It focuses on both cross-cutting and subgroup-specific questions, using an open-label, pragmatic design embedded in routine care.
BALANCE+ addresses the significant health concern of BSIs, which have high morbidity and mortality rates, exacerbated by the global public health threat of antimicrobial resistance (AMR). With rising resistance rates and limited new drug development, effective treatment strategies for BSIs remain under-researched.
BALANCE+ follows the BALANCE trial, which evaluated duration of antibiotic treatment, and aims to further investigate critical questions in managing Gram-negative BSIs. This platform trial will explore various aspects of BSI treatment, including antibiotic de-escalation, oral antibiotic choices, central line management, treatment of specific pathogens, and the necessity of follow-up blood cultures.
BALANCE+ is using Bayesian methods without a fixed sample size. Interim analyses will occur after every 1000th patient in each domain, and then for every 200th patient thereafter. The trial will stop if futility or superiority thresholds are met, or if a domain reaches its ceiling sample size (2500 patients for most domains and 4000 for the beta-lactam versus non-beta-lactam domain) without meeting a stopping threshold.
A vanguard pilot trial involving over 150 patients at 9 hospitals across Canada confirmed the feasibility of the BALANCE+ trial. The main trial will include patients from the vanguard pilot phase since there has been no major change in the overall study design and domains. The adaptive design allows for interim analyses and adjustments by adding or removing domains as per the statistical analysis plan, enhancing the trial's efficiency and relevance.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Nick Daneman, MD
- Telefonnummer: 3862 4164806100
- E-post: nick.daneman@sunnybrook.ca
Studer Kontakt Backup
- Navn: Mithun Mohan George
- Telefonnummer: 688153 416-480-6100
- E-post: mithun.george@sri.utoronto.ca
Studiesteder
-
-
New South Wales
-
Kogarah, New South Wales, Australia, 2217
- Rekruttering
- St George Hospital
-
Hovedetterforsker:
- Richard Sullivan
-
Ta kontakt med:
- Richard Sullivan
- Telefonnummer: +61 2 9113 1111
- E-post: richard.sullivan@health.nsw.gov.au
-
Underetterforsker:
- Pam Konecny
-
Ta kontakt med:
- Rachael Roberts, Research Coordinator
-
New Lambton, New South Wales, Australia
- Rekruttering
- John Hunter Hospital
-
Ta kontakt med:
- Joshua Davis
- E-post: Joshua.Davis@health.nsw.gov.au
-
Ta kontakt med:
- Telefonnummer: +61 2 4921 3000
-
Hovedetterforsker:
- Joshua Davis
-
-
Queensland
-
Herston, Queensland, Australia, 4006
- Rekruttering
- Royal Brisbane and Women's Hospital
-
Ta kontakt med:
- Patrick Harris, Infectious Disease Physician
- Telefonnummer: +61 7 3646 8111
- E-post: patrick.harris2@health.qld.gov.au
-
Hovedetterforsker:
- Patrick Harris, Infectious Disease Physician
-
Redcliffe, Queensland, Australia
- Rekruttering
- Redcliffe Hospital
-
Hovedetterforsker:
- Kevin O'Callaghan
-
Ta kontakt med:
- Kevin O'Callaghan
- Telefonnummer: +61 7 3883 7777
- E-post: Kevin.OCallaghan@health.qld.gov.au
-
Sunshine Coast, Queensland, Australia
- Rekruttering
- Sunshine Coast University Hospital
-
Ta kontakt med:
- Gururaj Nagaraj
- Telefonnummer: +61 7 5202 0000
- E-post: gururaj.nagaraj@health.oqld.gov.au
-
Hovedetterforsker:
- Gururaj Nagaraj
-
-
Victoria
-
Clayton, Victoria, Australia
- Rekruttering
- Monash Medical Center
-
Hovedetterforsker:
- Ben Rogers
-
Ta kontakt med:
- Ben Rogers
- Telefonnummer: (03) 9594 6666
- E-post: Ben.Rogers@monash.edu
-
-
Western Australia
-
Murdoch, Western Australia, Australia
- Rekruttering
- Fiona Stanley Hospital
-
Ta kontakt med:
- Edward Raby
- Telefonnummer: +61 8 6152 2222
- E-post: Edward.Raby@health.wa.gov.au
-
Hovedetterforsker:
- Edward Raby
-
Murdoch, Western Australia, Australia
- Rekruttering
- St John of God
-
Ta kontakt med:
- Adrian Regli
- Telefonnummer: +61 8 9438 9000
- E-post: adrian.regli@gmail.com
-
Hovedetterforsker:
- Adrian Regli
-
-
-
-
Alberta
-
Calgary, Alberta, Canada
- Rekruttering
- Rockyview General Hospital
-
Hovedetterforsker:
- Ranjani Somayaji
-
Ta kontakt med:
- Ranjani Somayaji
- Telefonnummer: (403) 943-3000
- E-post: rsomayaj@ucalgary.ca;kmfiest@ucalgary.ca
-
Calgary, Alberta, Canada
- Rekruttering
- Peter Lougheed Centre
-
Hovedetterforsker:
- Ranjani Somayaji
-
Ta kontakt med:
- Ranjani Somayaji
- Telefonnummer: (403) 943-4555
- E-post: rsomayaj@ucalgary.ca
-
Calgary, Alberta, Canada
- Rekruttering
- South Health Campus
-
Hovedetterforsker:
- Ranjani Somayaji
-
Ta kontakt med:
- Ranjani Somayaji
- Telefonnummer: (403) 956-1111
- E-post: rsomayaj@ucalgary.ca
-
Calgary, Alberta, Canada
- Rekruttering
- Foothills Hospital
-
Ta kontakt med:
- Ranjani Somayaji, MD
-
Edmonton, Alberta, Canada
- Rekruttering
- University of Alberta
-
Ta kontakt med:
- Wendy Sligl
- Telefonnummer: (780) 492-3111
- E-post: wsligl@ualberta.ca
-
Hovedetterforsker:
- Wendy Sligl
-
-
British Columbia
-
Surrey, British Columbia, Canada
- Rekruttering
- Surrey Memorial Hospital
-
Hovedetterforsker:
- Kevin Afra
-
Ta kontakt med:
- Kevin Afra
- Telefonnummer: (604) 581-2211
- E-post: Kevin.Afra@fraserhealth.ca
-
Vancouver, British Columbia, Canada
- Rekruttering
- Vancouver General Hospital
-
Hovedetterforsker:
- Jennifer Grant
-
Ta kontakt med:
- Jennifer Grant
- Telefonnummer: (604) 875-4111
- E-post: Jennifer.grant@bccdc.ca
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
- Rekruttering
- Health Sciences Centre
-
Ta kontakt med:
- Sylvain Lother
- Telefonnummer: (204) 787-3661
- E-post: Sylvain.Lother@umanitoba.ca
-
Hovedetterforsker:
- Sylvain Lother
-
Winnipeg, Manitoba, Canada
- Rekruttering
- St. Boniface Hospital
-
Hovedetterforsker:
- Terry Wuerz
-
Ta kontakt med:
- Terry Wuerz
- Telefonnummer: (204) 233-8563
- E-post: twuerz@hsc.mb.ca
-
Winnipeg, Manitoba, Canada
- Rekruttering
- Grace Hospital
-
Ta kontakt med:
- Gloria Vazquez-Grande
- Telefonnummer: (204) 837-0111
- E-post: Gloria.Vazquez-Grande@umanitoba.ca
-
Hovedetterforsker:
- Gloria Vazquez-Grande
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada
- Rekruttering
- Dr. Everett Chalmers Regional Hospital
-
Ta kontakt med:
- Rosa Rossana
- Telefonnummer: (506) 452-5400
- E-post: Rossana.Rosa@HorizonNB.ca
-
Hovedetterforsker:
- Rosa Rossana
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Canada
- Rekruttering
- Eastern Regional Health Authority
-
Ta kontakt med:
- Peter Daley, MD
-
-
Ontario
-
Mississauga, Ontario, Canada
- Rekruttering
- Trillium Health Partners - Mississauga Hospital
-
Ta kontakt med:
- Christopher Graham
- Telefonnummer: (905) 848-7100
- E-post: Christopher.Graham@thp.ca
-
Ta kontakt med:
- Mobina Khurram
-
Hovedetterforsker:
- Christopher Graham
-
North York, Ontario, Canada
- Rekruttering
- Humber River Health system
-
Ta kontakt med:
- Ian Brasg
- Telefonnummer: (416) 242-1000
- E-post: ibrasg@hrh.ca
-
Hovedetterforsker:
- Ian Brasg
-
North York, Ontario, Canada
- Rekruttering
- North York General Hospital
-
Ta kontakt med:
- Pavani Das
- Telefonnummer: (416) 756-6000
- E-post: Pavani.Das@nygh.on.ca
-
Hovedetterforsker:
- Pavani Das
-
Ottawa, Ontario, Canada
- Rekruttering
- The Ottawa Hospital
-
Ta kontakt med:
- Derek McFadden, MD
-
St. Catharines, Ontario, Canada
- Rekruttering
- Niagara Health System
-
Ta kontakt med:
- Aidan Findlater, MD
-
Toronto, Ontario, Canada
- Rekruttering
- University Health Network
-
Ta kontakt med:
- Bryan Coburn, MD
-
Toronto, Ontario, Canada, M4N3M5
- Rekruttering
- Sunnybrook Health Sciences Centre
-
Ta kontakt med:
- Nick Daneman, MD
- Telefonnummer: 2791 4164806100
- E-post: nick.daneman@sunnybrook.ca
-
Ta kontakt med:
- Archana Malavade
- Telefonnummer: 688153 416-480-6100
- E-post: archana.malavade@sri.utoronto.ca
-
Hovedetterforsker:
- Rob A Fowler, MD
-
Hovedetterforsker:
- Nick Daneman, MD
-
Toronto, Ontario, Canada
- Rekruttering
- Michael Garron Hospital
-
Ta kontakt med:
- Christopher Kandel, MD
-
Toronto, Ontario, Canada
- Rekruttering
- Mount Sinai Hospital
-
Ta kontakt med:
- Michael Fralick, PhD
-
Toronto, Ontario, Canada
- Rekruttering
- St. Joseph's Health Centre
-
Ta kontakt med:
- Kevin Schwartz
- Telefonnummer: (416) 530-6000
- E-post: Kevin.Schwartz@unityhealth.to
-
Hovedetterforsker:
- Kevin Schwartz
-
-
Quebec
-
Laval, Quebec, Canada
- Rekruttering
- Hôpital de la Cité de la Santé
-
Ta kontakt med:
- Marco Bergevin
- Telefonnummer: 450- 668-1010
- E-post: Marco-Andres.Bergevin.med@ssss.gouv.qc.ca
-
Hovedetterforsker:
- Marco Bergevin
-
Underetterforsker:
- Stéphanie Castonguay
-
Underetterforsker:
- Olivier Haeck
-
Underetterforsker:
- Esther Simoneau
-
Underetterforsker:
- Marios Roussos
-
Underetterforsker:
- Natalie Rivest
-
Underetterforsker:
- Tuyen Nguyen
-
Laval, Quebec, Canada
- Rekruttering
- CHU de Québec - Université Laval
-
Ta kontakt med:
- Francois Lauzier
- Telefonnummer: (418) 525-4444
- E-post: francois.lauzier@fmed.ulaval.ca
-
Hovedetterforsker:
- Francois Lauzier
-
Underetterforsker:
- Julie Bestman-Smith
-
Montreal, Quebec, Canada
- Rekruttering
- Montreal General Hospital- McGill
-
Ta kontakt med:
- Todd C Lee
- Telefonnummer: (514) 934-1934
- E-post: todd.lee@mcgill.ca
-
Hovedetterforsker:
- Todd C Lee
-
Hovedetterforsker:
- Emily Mcdonald
-
Montreal, Quebec, Canada
- Rekruttering
- Royal Victoria Hospital- McGill
-
Ta kontakt med:
- Todd C Lee
- Telefonnummer: (514) 934-1934
- E-post: todd.lee@mcgill.ca
-
Hovedetterforsker:
- Emily McDonald
-
Hovedetterforsker:
- Todd C Lee
-
Sherbrooke, Quebec, Canada
- Rekruttering
- Université de Sherbrooke
-
Ta kontakt med:
- François Lamontagne, MD
-
Trois-Rivières, Quebec, Canada, G8Z 3R9
- Rekruttering
- Centre hospitalier affilié universitaire régional (CHAUR)
-
Ta kontakt med:
- Jean-François Naud
- Telefonnummer: (819) 697-3333
- E-post: jean-francois.naud.med@ssss.gouv.qc.ca
-
Hovedetterforsker:
- Jean-François Naud
-
-
-
-
Cundinamarca
-
Chía, Cundinamarca, Colombia
- Rekruttering
- Universidad de La Sabana
-
Ta kontakt med:
- Luis Felipe Reyes Velasco
- Telefonnummer: +57 601 8615555
- E-post: luis.reyes5@unisabana.edu.co
-
Hovedetterforsker:
- Luis Felipe Reyes Velasco
-
-
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, Israel
- Rekruttering
- Sheba Medical Center
-
Hovedetterforsker:
- Dafna Yahav
-
Ta kontakt med:
- Dafna Yahav
- Telefonnummer: +972 3-530-3030
- E-post: dafna.yahav@gmail.com
-
-
-
-
Auckland
-
Auckland, Auckland, New Zealand, 2025
- Rekruttering
- Middlemore Hospital
-
Ta kontakt med:
- Susan Morpeth, Clinical Microbiologist
- Telefonnummer: +64 9 2709758
- E-post: Susan.Morpeth@middlemore.co.nz
-
Ta kontakt med:
- Aotearoa Clinical Trials
- Telefonnummer: +64 9 2709758
- E-post: grants@aotearoatrials.nz
-
Hovedetterforsker:
- Susan Morpeth, Clinical Microbiologist
-
Underetterforsker:
- Michael Trent Herdman, Specialist Registrar
-
Takapuna, Auckland, New Zealand, 0622
- Rekruttering
- North Shore Hospital
-
Ta kontakt med:
- Colin Menezes
- Telefonnummer: +64 9 486 8900
- E-post: colin.menezes@tewhatuora.govt.nz
-
Ta kontakt med:
- Umit Holland
- E-post: Umit.Holland@TeWhatuOra.govt.nz
-
Hovedetterforsker:
- Colin Menezes
-
-
Wellington Region
-
Newtown, Wellington Region, New Zealand, 6021
- Rekruttering
- Wellington Hospital
-
Ta kontakt med:
- Maxim Bloomfield
- Telefonnummer: +64 4 385 5999
- E-post: Maxim.Bloomfield@ccdhb.org.nz
-
Hovedetterforsker:
- Maxim Bloomfield
-
Underetterforsker:
- Paul Young
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
PLATFORM INCLUSION CRITERIA
Platform Inclusion Criteria:
- admitted to a participating hospital
- positive blood culture with Gram negative (GN) bacterium
Platform Exclusion Criteria:
- patient's goals of care are for palliation with no active treatment
- moribund patient, not expected to survive > 72 hours
- previously enrolled in the platform trial
- not eligible for any domain at the time of screening
DOMAIN SPECIFIC INCLUSION AND EXCLUSION CRITERIA
-
De-escalation versus no de-escalation domain
Inclusion Criteria
- included in BALANCE+ platform
Exclusion Criteria
-
receiving an empiric antibiotic regimen at the time of blood culture finalization to which the GN pathogen(s) are not sensitive
-
arbapenem-non-susceptible
-
no de-escalation option due to any or all of:
- antimicrobial resistance
- allergies
- medical contraindications
- drug-drug interaction risk
- other relevant reason
-
patients with a suspected or proven polymicrobial source of infection
-
> 24 hours since index blood culture susceptibility results finalization
-
-
Beta-lactam versus non-beta-lactam oral/enteral treatment domain
Inclusion Criteria
- included in BALANCE+ platform
- initially treated with intravenous antibiotics, but clinical team transitioning patient to oral/enteral antibiotic within 7 days of starting treatment
Exclusion Criteria
-
enrolled in an arm of another BALANCE+ platform domain which limits the use of oral/enteral therapy:
-
no-de-escalation arm (patients in the no de-escalation arm cannot be randomized into this domain unless they are ready for discharge home, in which case de-escalation is allowable to oral agents at discharge)
-
no non-beta-lactam options due to any or all of:
- resistance
- allergies
- medical contraindications
- drug-interaction risk
- other relevant reason
-
no beta-lactam options due to any or all of:
- resistance
- allergies
- medical contraindications
- drug-interaction risk
- other relevant reason
-
pregnancy
-
already received >24 hours of oral antibiotics after index blood culture finalization
-
Central vascular catheter replacement domain
Inclusion Criteria
- included in BALANCE+ platform
- has an indwelling central vascular catheter that was already in place within the 48-hour period before the onset of bloodstream infection (i.e. is not a new catheter placed within 48 hours of the onset of infection)
Exclusion Criteria
-
patient has no ongoing need for a central vascular catheter
-
patient has definite indication for central vascular catheter removal
-
ongoing septic shock with definite/probable line source o concomitant S. aureus bacteremia
- concomitant candidemia
-
local suppurative signs (severe redness, warmth, pain, swelling or fluctuance/collection) necessitating catheter removal, or other clinical evidence of infected line (e.g. imaging/echocardiographic findings)
-
Low-risk AmpC domain
Inclusion Criteria
- included in BALANCE+ platform
- positive blood culture with GN bacterium, of the following species: i. Serratia spp. ii Morganella spp. iii Providencia spp. iv Proteus spp. other than P.mirabilis
- organism is susceptible to ceftriaxone
Exclusion Criteria
- severe allergy to beta-lactams (e.g., type 4 hypersensitivity reaction or DRESS)
- baseline phenotypic non-susceptiblity to ceftriaxone
- more than 1 calendar day beyond availability of susceptibility results
-
Follow up blood culture domain
Inclusion Criteria
- included in BALANCE+ platform
Exclusion Criteria
- patient died or discharged from hospital prior to day 4
- blood culture already collected by the treating team at day 4±1
- >5 days since index positive blood culture collection
- definite indication for repeat blood culture testing o concomitant S. aureus bacteremia o concomitant Candidemia o clinical suspicion for infective endocarditis
-
4 day versus 7-day antibiotic duration
Inclusion Criteria • improving clinical trajectory, based on meeting all of these criteria by the 4th calendar day of adequate antibiotics:
o temperature 35.0ºC-37.9ºC
o not on vasopressors
o FiO2 ≤ 50%
Exclusion Criteria
• Has not undergone successful source control (if required) before completing 4th calendar day of adequate antibiotics
• Neutropenia (<0.5 × 10⁹/L)
- solid organ or bone marrow transplantation
- suspected or documented deep-seated infection requiring prolonged antibiotics
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Deeskalering VS Ingen Deeskalering
|
No de-escalation group: continue to receive the same antibiotic that was started initially (as long as it is confirmed to be effective based on the blood culture sensitivity result). De-escalation is only allowed within 7 days if patient is being discharged from hospital. De-escalation group: switched to narrower spectrum antibiotic (based on spectrum scale specified in protocol). |
|
Aktiv komparator: Orale beta-laktamer VS Orale Ikke-beta-laktamer
|
Beta-lactam antibiotic: This can be, but not limited to, amoxicillin, amoxicillin-clavulanate, cephalexin, cefadroxil, or cefixime. Non beta-lactam antibiotic: This can be ciprofloxacin, moxifloxacin, levofloxacin or trimethoprim-sulfamethoxazole. |
|
Aktiv komparator: Sentralt karkateterretensjon VS Utskifting av sentralvaskulær kateter
|
Central vascular catheter replacement: the catheter will be changed by the treating team as soon as possible and within a maximum of 3 calendar days from blood culture finalization (removal must happen within that time; replacement can occur after that time point) Central vascular catheter retention: the catheter will not be changed and will be retained until it is non functional or no longer needed. |
|
Aktiv komparator: Cephalosporin VS Carbapenem for lavrisiko AmpC-organismer
|
Cephalosporin (ceftriaxone) at standard doses Carbapenem (Meropenem or Ertapenem) at standard doses |
|
Aktiv komparator: Routine follow-up blood culture VS No routine follow-up blood culture
Enrollment to the domain has been completed. |
Routine follow-up blood culture: routine repeat blood collection 4 days from the index blood collection with positive bacteria. No follow-up blood culture: no routine repeat blood collection 4 days from the index blood collection with positive bacteria |
|
Aktiv komparator: 4-day versus 7-day antibiotic duration
|
The shorter duration arm will receive 4 days of adequate antibiotics. The longer duration arm will receive 7 days of adequate antibiotics. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Desirability of Outcome Ranking (DOOR) Ordinal Scale which incorporates death, reinfection, readmission, and for some domains incorporates a tie-breaker of new antimicrobial resistance (AMR).
Tidsramme: 90 days
|
The primary outcome for each domain will use a Desirability of Outcome Ranking (DOOR) ordinal scale in which patients are categorized into the following mutually exclusive categories, ranked from best to worst status:
For the 4 antibiotic-related domains (the de-escalation versus no de-escalation domain, the beta-lactam versus non-beta-lactam domain, the low risk AmpC domain, and the 4 versus 7 day duration domain) there will be an additional tie-breaker within ordinal levels 1, 2 and 3 based on whether there was new detection of antimicrobial resistance (AMR). |
90 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
30 dagers dødelighet
Tidsramme: 30 dager
|
30 dager
|
|
|
90-dagers dødelighet
Tidsramme: 90 dager
|
90 dager
|
|
|
60 dagers dødelighet
Tidsramme: 60 dager
|
60 dager
|
|
|
90 dager forårsaker alle reinnleggelse
Tidsramme: 90 dager
|
90 dager
|
|
|
90-dagers AMR-kolonisering/infeksjon
Tidsramme: 90 dager
|
90 dager
|
|
|
90-dagers Clostridioides difficile-infeksjon (CDI)
Tidsramme: 90 dager
|
90 dager
|
|
|
90-dagers re-infeksjon
Tidsramme: 90 dager
|
90 dager
|
|
|
Additional Secondary Outcomes for Follow up blood culture domain
Tidsramme: 90 days
|
|
90 days
|
|
Additional Secondary Outcomes for De-escalation versus no de-escalation Domain
Tidsramme: 90 days
|
|
90 days
|
|
Additional Secondary Outcomes for Beta-lactam versus non-beta-lactam domain
Tidsramme: 90 days
|
|
90 days
|
|
Additional Secondary Outcomes for Central vascular catheter replacement versus retention domain
Tidsramme: 90 days
|
|
90 days
|
|
Additional Secondary Outcomes for Low-risk AmpC domain
Tidsramme: 90 days
|
|
90 days
|
|
Additional domain-specific secondary outcomes in 4-day versus 7-day antibiotic duration
Tidsramme: 90 days
|
|
90 days
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Nick Daneman, MD, Sunnybrook Health Sciences Centre
- Hovedetterforsker: Rob Fowler, MD, Sunnybrook Health Sciences Centre
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- 4369-1
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .